Christopher Posner, PRESIDENT AND CEO at Cara Therapeutics, Inc. (CARA), sold 583 shares at $4.75 ($3K) on 2025-02-28, disclosed to the SEC on 2025-03-04.
Scheduled sale ($3k) by PRESIDENT AND CEO under a pre-arranged 10b5-1 plan. Pre-set trade — not a discretionary signal on the stock.
Negative factors outweigh the positive ones.
| Filing → |
| CARA | SELL | 2024-08-02 | $1K | — | Filing → |
| CARA | SELL | 2024-05-06 | $3K | — | Filing → |
| CARA | SELL | 2024-03-04 | $5K | — | Filing → |